Cardiovascular implications of HIV-associated dyslipidemic lipodystrophy

被引：14
|
作者：
Sekhar R.V. [1 ]
Jahoor F. [1 ]
Pownall H.J. [1 ]
Ballantyne C.M. [1 ]
Balasubramanyam A. [1 ]
机构：
[1] Division of Endocrinology, Baylor College of Medicine, Houston, TX 77030, One Baylor Plaza
来源：
Current Atherosclerosis Reports | 2004年 / 6卷 / 3期
基金：
美国国家卫生研究院;
关键词：
Insulin Resistance; Cholesteryl Ester Transfer Protein; Lipodystrophy; Postprandial Lipemia; Intramyocellular Lipid;
D O I：
10.1007/s11883-004-0029-2
中图分类号：
学科分类号：
摘要：
The emergence of a new metabolic syndrome in patients with HIV infection, termed "HIV-associated dyslipidemic lipodystrophy" (HADL), is characterized by central fat redistribution, severe dyslipidemia, and insulin resistance and predisposes to an increased risk of cardiovascular disease. The factors promoting the development of cardiovascular disease in this condition are not well understood and may involve contributions from antiretroviral drugs and components of the HIV virus, as well as inflammatory cytokines, leading to accelerated lipolysis, dyslipidemia, lipotoxic insulin resistance, and vascular inflammation. In this article, we review HADL in terms of metabolic, molecular, and cytokine derangements leading to cardiovascular disease. Copyright © 2004 by Current Science Inc.
引用
收藏
页码：173 / 179
页数：6
相关论文
共 50 条
  • [41] Role of FAP48 in HIV-associated lipodystrophy
    Esposito, Vincenzo
    Manente, Lucrezia
    Lucariello, Angela
    Perna, Angelica
    Viglietti, Rosaria
    Gargiulo, Miriam
    Parrella, Roberto
    Parrella, Giovanni
    Baldi, Alfonso
    De Luca, Antonio
    Chirianni, Antonio
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2012, 113 (11) : 3446 - 3454
  • [42] Psychopathology and psychosocial adjustment in patients with HIV-associated lipodystrophy
    Barata, Anna
    Malouf, Jorge
    Gutierrez, Mar
    Maria Mateo, Gracia
    Antonia Sambeat, Maria
    Gich, Ignasi
    Cadafalch, Josep
    Wulff, Juan
    Domingo, Pere
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (04): : 444 - 449
  • [43] Prevalence of HIV-associated lipodystrophy in Brazilian outpatients: Relation with metabolic syndrome and cardiovascular risk factors
    Diehl, Leandro A.
    Dias, Janaina R.
    Paes, Aline C. S.
    Thomazini, Maria C.
    Garcia, Lorena R.
    Cinagawa, Eduardo
    Wiechmann, Susana L.
    Carrilho, Alexandre J. F.
    ARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2008, 52 (04) : 658 - 667
  • [44] The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection
    Guaraldi, G.
    Stentarelli, C.
    Zona, S.
    Santoro, A.
    Beghetto, B.
    Carli, F.
    Orlando, G.
    Franceschetto, A.
    Casolo, A.
    Mussini, C.
    HIV MEDICINE, 2014, 15 (10) : 587 - 594
  • [45] Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Mallon, PWG
    Wand, H
    Law, M
    Miller, J
    Cooper, DA
    Carr, A
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 38 (02) : 156 - 162
  • [46] HIV-associated lipodystrophy syndrome: overview and summary of case reports
    Reid, S
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2002, 166 (01) : 87 - 88
  • [47] TesamorelinA Review of its Use in the Management of HIV-Associated Lipodystrophy
    Sohita Dhillon
    Drugs, 2011, 71 : 1071 - 1091
  • [48] A 39-year-old man with HIV-associated lipodystrophy
    Fuller, Jon
    Libman
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (09): : 1056 - 1066
  • [49] Statins in HIV-associated lipodystrophy and metabolic syndrome: is there a missing link?
    Gharakhanian, Shahin
    Boccara, Franck
    Capeau, Jacqueline
    AIDS, 2006, 20 (07) : 1061 - 1063
  • [50] HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options
    Mallewa, Jane E.
    Wilkins, Edmund
    Vilar, Javier
    Mallewa, Macpherson
    Doran, Dominic
    Back, David
    Pirmohamed, Munir
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (04) : 648 - 660
12345